Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-01-31
Study Completion Date
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
BRIEF SUMMARY
Canadians often visit areas with malaria where the preventative drug chloroquine no longer works.
This leaves Canadians with the choice to use three different drugs to prevent malaria - atovaquone-proguanil, doxycycline, or mefloquine. There are more than 400 cases of malaria reported in Canada each year, a few which result in death. These cases mainly occur in people who do not take malaria pills as directed.
Investigators have developed the Ottawa Malaria Decision Aid (OMDA), which is a bilingual (English and French) resource used to support malaria prevention decision-making. The OMDA contains plain language, fact-based information and helps individuals to reflect on their own values and beliefs so that they can make the best decision for their situation.
In this randomized control study, the investigators will attempt to find out if using the OMDA before visiting a travel clinic affects decisional conflict and the way pills are taken. Consenting travellers will be assigned to standard care or standard care plus the malaria decision aid. Both groups will complete three questionnaires before and after travel to look at the impact on decisional conflict, preparation for decision-making, decisional regret and pill taking behaviour.
Travelers' malaria can be prevented. It is our hope that by using different methods of presenting information, specifically by utilizing the OMDA, there will be an increase in adherence to appropriate malaria prophylaxis which will ultimately result in a decrease in malaria cases that arrive in Canada. This will translate into a decreased use of health care dollars and unnecessary deaths.
The Objectives of this study are to evaluate whether the malaria decision aid can be integrated into the pre-travel consultation process and can:
* improve a traveller's knowledge of malaria and prevention strategies;
* improve a traveller's preparation for decision-making;
* decrease decisional conflict; and
* affect levels of adherence to prescribed malaria chemoprophylaxis.
The hypotheses of this study are that:
1. A decision aid will improve the quality of decision-making about malaria chemoprophylaxis by decreasing decisional conflict and increasing knowledge about malaria and malaria pills.
2. Better decision quality will result in a greater level of adherence to prescribed malaria chemoprophylaxis.
Canadians often visit areas with malaria where the preventative drug chloroquine no longer works.
This leaves Canadians with the choice to use three different drugs to prevent malaria - atovaquone-proguanil, doxycycline, or mefloquine. There are more than 400 cases of malaria reported in Canada each year, a few which result in death. These cases mainly occur in people who do not take malaria pills as directed.
Investigators have developed the Ottawa Malaria Decision Aid (OMDA), which is a bilingual (English and French) resource used to support malaria prevention decision-making. The OMDA contains plain language, fact-based information and helps individuals to reflect on their own values and beliefs so that they can make the best decision for their situation.
In this randomized control study, the investigators will attempt to find out if using the OMDA before visiting a travel clinic affects decisional conflict and the way pills are taken. Consenting travellers will be assigned to standard care or standard care plus the malaria decision aid. Both groups will complete three questionnaires before and after travel to look at the impact on decisional conflict, preparation for decision-making, decisional regret and pill taking behaviour.
Travelers' malaria can be prevented. It is our hope that by using different methods of presenting information, specifically by utilizing the OMDA, there will be an increase in adherence to appropriate malaria prophylaxis which will ultimately result in a decrease in malaria cases that arrive in Canada. This will translate into a decreased use of health care dollars and unnecessary deaths.
The Objectives of this study are to evaluate whether the malaria decision aid can be integrated into the pre-travel consultation process and can:
* improve a traveller's knowledge of malaria and prevention strategies;
* improve a traveller's preparation for decision-making;
* decrease decisional conflict; and
* affect levels of adherence to prescribed malaria chemoprophylaxis.
The hypotheses of this study are that:
1. A decision aid will improve the quality of decision-making about malaria chemoprophylaxis by decreasing decisional conflict and increasing knowledge about malaria and malaria pills.
2. Better decision quality will result in a greater level of adherence to prescribed malaria chemoprophylaxis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chloroquine Alone or in Combination for Malaria in Children in Malawi
NCT00379821
Plasmodium Falciparum Infection
COMPLETED
PHASE3
Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.
NCT00367653
Malaria
COMPLETED
PHASE3
Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
NCT01236612
Plasmodium Falciparum Malaria
COMPLETED
NA
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa
NCT00082576
Malaria, Falciparum
COMPLETED
PHASE2/PHASE3
Safety and Efficacy of Primaquine for P. Vivax
NCT01837992
Malaria
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
RECRUITMENT
The participants will be recruited from the travel medicine clinic at The Ottawa Hospital General Campus, the National Capital Region Occupational Health Clinic, and through The International Association for Medical Assistance to Travellers (IAMAT), a non-profit organization dedicated to travel health. The study will undergo a recruitment process that is estimated to last for approximately one year, or until at least 100 patients complete all three questionnaires.
Recruitment begins at the time of initial contact with the travel clinic or IAMAT. Travelers routinely phone, email or fax the travel clinic to book their pre-travel consultation and the clerk at the clinic records pertinent information.
Recruitment at The Ottawa Hospital - General Campus Recruitment begins at the time of initial contact with the travel clinic. Travellers routinely phone the travel clinic to book their pre-travel consultation and the clerk at the clinic records pertinent information. At the time of booking, the clerk fills out a "Traveller Information Form", which contains an individual's name and contact information, lists the dates they will travel, and the countries that they plan to travel to. All travelers will be asked by the clerk if they would agree to be contacted by a researcher for a study. If they say yes, and the countries listed on the form are in line with those chosen for recruiting participants, the research assistant will contact them by the email or telephone number listed. The research assistant will send/read an email/telephone script which introduces the study and will ask participants if they would be interested in learning more. If they say yes, they will be provided with the study website information (a small paragraph describing the study with a link to study registration). Because the investigators recognize the difficulty of writing down website addresses, the traveller will have the option to provide the research assistant with their email address, if the research assistant does not have it already, and have the study website address sent to them electronically by the research assistant. The research assistant will not retain any personal information for any clients contacted at any time in the recruitment stage. The only information collected during recruitment will be the net number of clients called/emailed, and the net number who indicated that they would be interested in participating.
Recruitment at the National Capital Region Clinic Recruitment begins at the time of initial contact with the travel clinic. Travellers routinely email the travel clinic. Then they are sent a form to complete and email or fax. For all travellers planning to visit an area with chloroquine-resistant malaria for one year or less, the clerk will send an email attachment of the study recruitment information, including the study website information. No personal information about the individuals contacted will be collected by the study team. The clerk only will relay the net number of individuals contacted to the study research assistant.
Recruitment through travel health advertising: eNewsletters and social media Recruitment will begin through social media and email newsletters to subscribing members. Travel medicine associations with members who subscribe to receive travel health information will post the recruitment script in eNewsletters and on social media websites as part of their normal advertising procedures. When travellers observe the recruitment script in the newsletter or on a social media website, they can click on the link located within it, which will bring them to the study website. If they pass the eligibility criteria, individuals are invited to proceed to complete the recruitment process as described below.
An example of one organization which will post the recruitment message is The International Association for Medical Assistance to Travellers (IAMAT), a non-profit organization dedicated to travel health. IAMAT specializes in providing pre-trip travel health advice and coordinates an international network of physicians and travel clinics. IAMAT would add the currently approved recruitment text to their eNewsletter, and put the text on their social media websites. Only subscribing members to their email listserv or visitors to their social media accounts will receive the information about the study.
\----------
STUDY PROGRESSION
All potential study participants will be sent a link by email to the study website. In the case of IAMAT, subscribing members will receive information about the study containing the study link. Upon clicking on the link, they will be directed to the traveler information and consent form page. The page contains information about why the research is being conducted, the purpose of the study, a description of the study, outlines the risks and benefits of participation, and asks participants for voluntary consent to participate.
If interested in participating, then they will be asked to acknowledge that they have reviewed the traveler information and consent form page. Those agreeing to participate will be directed to an eligibility page. They will be asked questions to ensure that they are eligible for study participation. If they are eligible, they will be invited to participate and register their email address for the study. They will be informed that by logging on to the website, they will be providing their implied consent for participation in the study.
Once a participant enters their registration information, they will be sent a link to their email address that they must click on in order to begin the first survey.
All groups will complete all three surveys at the times described below. The randomization process will take place during the Baseline survey.
* The Baseline survey is to be done before the pre-travel clinic consultation;
* The Post-Consult survey is to be completed immediately after the travel medicine consultation; and
* The Post-chemoprophylaxis questionnaire is to be completed one week after the expected date of finishing chemoprophylaxis.
Once a participant completes all three surveys, in return for their time and dedication to the study, participants who reside in Canada will be offered a $5 gift card to a popular Canadian coffee chain (Tim Horton's).
\----------
RANDOMIZATION PROCESS
Upon beginning the Baseline questionnaire, all participants will be randomized centrally into two groups.
* Group 1 will receive standard pre-travel information through the pre-travel consultation process.
* Group 2 will receive The Ottawa Malaria Decision Aid plus standard pre-travel information through the pre-travel consultation process.
For those randomized to Group 2, the decision aid has been embedded in the baseline survey. The Decision Aid provides comparative information about malaria pill options; communicates probabilities for the risk of malaria; and clarifies values.
All other questionnaires and standard medical care will remain the same for both groups of participants.
\----------
CONFIDENTIALITY
All data collected will be coded with an independent study number and kept anonymous. The file linking codes to patient names will be stored in a locked filling cabinet at The Ottawa Hospital and stored separately from the main project files in one of Dr. McCarthy's offices. Only the research team will have access to these files.
Electronic files will contain anonymized information and will be password protected and stored in the secure TOH servers behind the The Ottawa Hospital firewall. These data will only contain assigned study numbers to identify data sets. Only the research team will have access to this information.
Study records may be audited by the Ottawa Hospital Research Ethics Board (OHREB).
Participants will not be able to be identified in any of the publications resulting from this project.
\----------
PATIENT RISK
There are no risks anticipated in this study. Participation in the study is voluntary and will not affect the participant's routine medical care. Patients expressing concerns about the information in the decision aid will be referred to their individual physician or travel clinic physician or nurse.
The participants will be recruited from the travel medicine clinic at The Ottawa Hospital General Campus, the National Capital Region Occupational Health Clinic, and through The International Association for Medical Assistance to Travellers (IAMAT), a non-profit organization dedicated to travel health. The study will undergo a recruitment process that is estimated to last for approximately one year, or until at least 100 patients complete all three questionnaires.
Recruitment begins at the time of initial contact with the travel clinic or IAMAT. Travelers routinely phone, email or fax the travel clinic to book their pre-travel consultation and the clerk at the clinic records pertinent information.
Recruitment at The Ottawa Hospital - General Campus Recruitment begins at the time of initial contact with the travel clinic. Travellers routinely phone the travel clinic to book their pre-travel consultation and the clerk at the clinic records pertinent information. At the time of booking, the clerk fills out a "Traveller Information Form", which contains an individual's name and contact information, lists the dates they will travel, and the countries that they plan to travel to. All travelers will be asked by the clerk if they would agree to be contacted by a researcher for a study. If they say yes, and the countries listed on the form are in line with those chosen for recruiting participants, the research assistant will contact them by the email or telephone number listed. The research assistant will send/read an email/telephone script which introduces the study and will ask participants if they would be interested in learning more. If they say yes, they will be provided with the study website information (a small paragraph describing the study with a link to study registration). Because the investigators recognize the difficulty of writing down website addresses, the traveller will have the option to provide the research assistant with their email address, if the research assistant does not have it already, and have the study website address sent to them electronically by the research assistant. The research assistant will not retain any personal information for any clients contacted at any time in the recruitment stage. The only information collected during recruitment will be the net number of clients called/emailed, and the net number who indicated that they would be interested in participating.
Recruitment at the National Capital Region Clinic Recruitment begins at the time of initial contact with the travel clinic. Travellers routinely email the travel clinic. Then they are sent a form to complete and email or fax. For all travellers planning to visit an area with chloroquine-resistant malaria for one year or less, the clerk will send an email attachment of the study recruitment information, including the study website information. No personal information about the individuals contacted will be collected by the study team. The clerk only will relay the net number of individuals contacted to the study research assistant.
Recruitment through travel health advertising: eNewsletters and social media Recruitment will begin through social media and email newsletters to subscribing members. Travel medicine associations with members who subscribe to receive travel health information will post the recruitment script in eNewsletters and on social media websites as part of their normal advertising procedures. When travellers observe the recruitment script in the newsletter or on a social media website, they can click on the link located within it, which will bring them to the study website. If they pass the eligibility criteria, individuals are invited to proceed to complete the recruitment process as described below.
An example of one organization which will post the recruitment message is The International Association for Medical Assistance to Travellers (IAMAT), a non-profit organization dedicated to travel health. IAMAT specializes in providing pre-trip travel health advice and coordinates an international network of physicians and travel clinics. IAMAT would add the currently approved recruitment text to their eNewsletter, and put the text on their social media websites. Only subscribing members to their email listserv or visitors to their social media accounts will receive the information about the study.
\----------
STUDY PROGRESSION
All potential study participants will be sent a link by email to the study website. In the case of IAMAT, subscribing members will receive information about the study containing the study link. Upon clicking on the link, they will be directed to the traveler information and consent form page. The page contains information about why the research is being conducted, the purpose of the study, a description of the study, outlines the risks and benefits of participation, and asks participants for voluntary consent to participate.
If interested in participating, then they will be asked to acknowledge that they have reviewed the traveler information and consent form page. Those agreeing to participate will be directed to an eligibility page. They will be asked questions to ensure that they are eligible for study participation. If they are eligible, they will be invited to participate and register their email address for the study. They will be informed that by logging on to the website, they will be providing their implied consent for participation in the study.
Once a participant enters their registration information, they will be sent a link to their email address that they must click on in order to begin the first survey.
All groups will complete all three surveys at the times described below. The randomization process will take place during the Baseline survey.
* The Baseline survey is to be done before the pre-travel clinic consultation;
* The Post-Consult survey is to be completed immediately after the travel medicine consultation; and
* The Post-chemoprophylaxis questionnaire is to be completed one week after the expected date of finishing chemoprophylaxis.
Once a participant completes all three surveys, in return for their time and dedication to the study, participants who reside in Canada will be offered a $5 gift card to a popular Canadian coffee chain (Tim Horton's).
\----------
RANDOMIZATION PROCESS
Upon beginning the Baseline questionnaire, all participants will be randomized centrally into two groups.
* Group 1 will receive standard pre-travel information through the pre-travel consultation process.
* Group 2 will receive The Ottawa Malaria Decision Aid plus standard pre-travel information through the pre-travel consultation process.
For those randomized to Group 2, the decision aid has been embedded in the baseline survey. The Decision Aid provides comparative information about malaria pill options; communicates probabilities for the risk of malaria; and clarifies values.
All other questionnaires and standard medical care will remain the same for both groups of participants.
\----------
CONFIDENTIALITY
All data collected will be coded with an independent study number and kept anonymous. The file linking codes to patient names will be stored in a locked filling cabinet at The Ottawa Hospital and stored separately from the main project files in one of Dr. McCarthy's offices. Only the research team will have access to these files.
Electronic files will contain anonymized information and will be password protected and stored in the secure TOH servers behind the The Ottawa Hospital firewall. These data will only contain assigned study numbers to identify data sets. Only the research team will have access to this information.
Study records may be audited by the Ottawa Hospital Research Ethics Board (OHREB).
Participants will not be able to be identified in any of the publications resulting from this project.
\----------
PATIENT RISK
There are no risks anticipated in this study. Participation in the study is voluntary and will not affect the participant's routine medical care. Patients expressing concerns about the information in the decision aid will be referred to their individual physician or travel clinic physician or nurse.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Malaria
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Care
This arm will receive no intervention; only standard medical care.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Decision Aid + Standard Care
This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care.
Group Type
EXPERIMENTAL
Ottawa Malaria Decision Aid
Intervention Type
OTHER
The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ottawa Malaria Decision Aid
The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An Adult 18 years of age or older
* Individuals who have contacted the travel clinic at The Ottawa Hospital, General Campus, the National Capital Region Occupational Health Clinic or received study information from IAMAT before they travel
* Travelling for less than one year
* Departing for the trip in more than one week
* Travelling to an area with known chloroquine-resistant malaria
* Individuals who have contacted the travel clinic at The Ottawa Hospital, General Campus, the National Capital Region Occupational Health Clinic or received study information from IAMAT before they travel
* Travelling for less than one year
* Departing for the trip in more than one week
* Travelling to an area with known chloroquine-resistant malaria
Exclusion Criteria
* The travellers not visiting areas with chloroquine resistant malaria
* Those travelling longer than one year
* Departing for the trip in less than one week
* Individuals younger than 18 years of age
* Those who are pregnant or intend to become pregnant during their travel
* Those who have severe kidney disease, severe liver disease, heart rhythm problems, or a history of seizures
* Those who have a history of mental problems
* Those who have an allergy to Atovaquone-proguanil, Doxycycline or Mefloquine
* Those who are unable to understand written or spoken English or French due to deafness, blindness, cognitive impairment or language barrier
* Those travelling longer than one year
* Departing for the trip in less than one week
* Individuals younger than 18 years of age
* Those who are pregnant or intend to become pregnant during their travel
* Those who have severe kidney disease, severe liver disease, heart rhythm problems, or a history of seizures
* Those who have a history of mental problems
* Those who have an allergy to Atovaquone-proguanil, Doxycycline or Mefloquine
* Those who are unable to understand written or spoken English or French due to deafness, blindness, cognitive impairment or language barrier
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ottawa Hospital Research Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne E McCarthy, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
The Ottawa Hospital Research Institute
Catherine Ivory, PhD
Role: STUDY_CHAIR
University of Ottawa, Faculty of Medicine
Louise Balfour, PhD
Role: STUDY_CHAIR
Ottawa Hospital Research Institute
Charde A Morgan, MScPH
Role: STUDY_CHAIR
Ottawa Hospital Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Capital Region Occupational Health Clinic
Ottawa, Ontario, Canada
Site Status
RECRUITING
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Site Status
RECRUITING
International Association for Medical Assistance to Travellers
Toronto, Ontario, Canada
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Committee to Advise on Tropical Medicine and Travel (CATMAT). Canadian recommendations for the prevention and treatment of malaria among international travellers--2009. Can Commun Dis Rep. 2009 Jul;35 Suppl 1:1-82. No abstract available.
Reference Type
BACKGROUND
Steffen R, deBernardis C, Banos A. Travel epidemiology--a global perspective. Int J Antimicrob Agents. 2003 Feb;21(2):89-95. doi: 10.1016/s0924-8579(02)00293-5.
Reference Type
BACKGROUND
Conner BA. Expert recommendations for antimalarial prophylaxis. J Travel Med. 2001 Dec;8(Suppl 3):S57-64. No abstract available.
Reference Type
BACKGROUND
Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 1998 Mar 7;351(9104):709-13. doi: 10.1016/S0140-6736(97)09222-2.
Reference Type
BACKGROUND
Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD; Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis. 2001 Oct 1;33(7):1015-21. doi: 10.1086/322694. Epub 2001 Sep 5.
Reference Type
BACKGROUND
Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003 Nov 8;327(7423):1078. doi: 10.1136/bmj.327.7423.1078.
Reference Type
BACKGROUND
Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg. 1999 Apr;60(4):521-5. doi: 10.4269/ajtmh.1999.60.521.
Reference Type
BACKGROUND
Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D, Scott TR. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis. 1998 Sep;27(3):494-9. doi: 10.1086/514710.
Reference Type
BACKGROUND
Sossouhounto RT, Soro BN, Coulibaly A, Mittelholzer ML, Stuerchler D, Haller L. Mefloquine in the Prophylaxis of P. Falciparum Malaria. J Travel Med. 1995 Dec 1;2(4):221-224. doi: 10.1111/j.1708-8305.1995.tb00663.x.
Reference Type
BACKGROUND
Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis. 2003 Mar 1;36(5):541-9. doi: 10.1086/367542. Epub 2003 Feb 14.
Reference Type
BACKGROUND
Suh KN, Kain KC, Keystone JS. Malaria. CMAJ. 2004 May 25;170(11):1693-702. doi: 10.1503/cmaj.1030418.
Reference Type
BACKGROUND
Landry P, Iorillo D, Darioli R, Burnier M, Genton B. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox. J Travel Med. 2006 Jan-Feb;13(1):8-14. doi: 10.1111/j.1708-8305.2006.00005.x.
Reference Type
BACKGROUND
Morgan M, Figueroa-Munoz JI. Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study. Ethn Health. 2005 Nov;10(4):355-72. doi: 10.1080/13557850500242035.
Reference Type
BACKGROUND
O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Khangura S, Llewellyn-Thomas H, Rovner D. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001431. doi: 10.1002/14651858.CD001431.pub2.
Reference Type
BACKGROUND
Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R, Barratt A, Barry M, Bernstein S, Butow P, Clarke A, Entwistle V, Feldman-Stewart D, Holmes-Rovner M, Llewellyn-Thomas H, Moumjid N, Mulley A, Ruland C, Sepucha K, Sykes A, Whelan T; International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006 Aug 26;333(7565):417. doi: 10.1136/bmj.38926.629329.AE. Epub 2006 Aug 14.
Reference Type
BACKGROUND
Laupacis A, O'Connor AM, Drake ER, Rubens FD, Robblee JA, Grant FC, Wells PS. A decision aid for autologous pre-donation in cardiac surgery--a randomized trial. Patient Educ Couns. 2006 Jun;61(3):458-66. doi: 10.1016/j.pec.2005.05.014. Epub 2005 Jul 15.
Reference Type
BACKGROUND
White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014 Feb 22;383(9918):723-35. doi: 10.1016/S0140-6736(13)60024-0. Epub 2013 Aug 15.
Reference Type
BACKGROUND
Chiodini PL, Field VK, Hill DR, Whitty CJM and Lalloo DG. Guidelines for malaria prevention in travellers from the United Kingdom. London, Public Health England, July 2013.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.ottawahospital.on.ca/
The Ottawa Hospital
http://www.ohri.ca/home.asp
The Ottawa Hospital Research Institute
http://decisionaid.ohri.ca/
Patient Decision Aids at The Ottawa Hospital Research Institute
http://www.ccohs.ca/
Canadian Centre for Occupational Health and Safety
http://www.iamat.org/
International Association for Medical Assistance to Travellers
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010462-01H
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model
NCT03707041
COMPLETED
PHASE1
Weekly Dosing of Malarone ® for Prevention of Malaria
NCT00984256
COMPLETED
PHASE2
Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial
NCT00373048
COMPLETED
NA
Short Course Radical Cure of P. Vivax Malaria in Nepal
NCT04079621
COMPLETED
PHASE4
Eight Week Primaquine Regimen for the Treatment of Vivax Malaria
NCT00158587
COMPLETED
PHASE3
Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
NCT01728701
COMPLETED
PHASE1
Evaluating the Role of Chloroquine for Malaria Elimination
NCT02698748
COMPLETED
PHASE2/PHASE3
Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects
NCT01218932
COMPLETED
PHASE1
Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis
NCT02858817
COMPLETED
PHASE1
Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine
NCT00970879
COMPLETED
PHASE3
Single Low-dose Primaquine Efficacy and Safety.
NCT03352843
COMPLETED
PHASE4
Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria
NCT02389439
COMPLETED
PHASE2
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
NCT00084227
COMPLETED
PHASE2/PHASE3
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
NCT00677833
COMPLETED
PHASE2/PHASE3
A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
NCT00282919
COMPLETED
PHASE2
Comparison of Three Plasmodium Falciparum Isolates in a Controlled Human Malaria Infection
NCT01627951
COMPLETED
NA
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
NCT01858831
COMPLETED
PHASE1
Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
NCT01213966
COMPLETED
PHASE2
Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan
NCT01716260
COMPLETED
A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine
NCT00844207
COMPLETED
PHASE1
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
NCT02431650
COMPLETED
PHASE1/PHASE2
Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects
NCT01525511
COMPLETED
PHASE1
Cotrifazid Safety and Efficacy Against Malaria
NCT00322907
TERMINATED
PHASE2
Drug Combinations of Atovaquone-Proguanil (AP) With ACT
NCT03726593
UNKNOWN
PHASE4
A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265
NCT02389348
COMPLETED
PHASE1/PHASE2